Table 3 Observed and expected numbers of death in 696 acrylamide employees in the total cohort.
| Cause of death | Obs | Exp | SMR (95% CI) |
|---|---|---|---|
| All causes | 141 | 172.1 | 81.9 (69.0–96.6) |
| All malignant neoplasms | 43 | 45.4 | 94.8 (68.6–127.7) |
| Buccal cavity and pharynx | 1 | 1.1 | 90.1 (2.3–502.2) |
| Digestive organs and peritoneum | 17 | 10.9 | 155.5 (90.6–249.0) |
| Oesophagus | 0 | 1.3 | – (0.0–275.8) |
| Stomach | 1 | 1.4 | 73.1 (1.8–407.5) |
| Large intestine | 7 | 3.7 | 187.5 (75.4–386.3) |
| Rectum | 2 | 0.8 | 242.6 (29.4–876.5) |
| Biliary passages and liver | 1 | 1.1 | 89.4 (2.2–498.3) |
| Pancreas | 5 | 2.3 | 222.2 (72.1–518.5) |
| All other digestive organs | 1 | 0.3 | 333.0 (8.3–1855.2) |
| Respiratory system | 12 | 17.0 | 70.5 (36.4–123.2) |
| Bronchus, trachea, lung | 12 | 16.3 | 73.7 (38.1–128.7) |
| Prostate | 1 | 3.0 | 33.7 (0.8–187.8) |
| Kidney | 3 | 1.2 | 245.3 (50.6–716.9) |
| Bladder or other urinary organs | 1 | 1.0 | 96.5 (2.4–538.0) |
| Malignant melanoma | 1 | 0.9 | 114.1 (2.9–635.9) |
| Central nervous system | 0 | 1.4 | – (0.0–264.8) |
| Thyroid and other endocrine glands | 1 | 0.1 | 719.4 (18.0–4008.3) |
| Bone | 0 | 0.1 | – (0.0–3293.8) |
| All lymphatic and haematopoetic | 4 | 4.5 | 89.8 (24.5–230.0) |
| Non‐malignant diseases | |||
| Diabetes mellitus | 10 | 3.5 | 288.7 (138.4–531.0) |
| Cerebrovascular disease | 5 | 7.7 | 65.3 (21.2–152.30 |
| Heart disease | 54 | 58.9 | 91.8 (68.9–119.7) |
| Non‐malignant respiratory disease | 6 | 12.2 | 49.2 (18.1–107.1) |
| All external causes | 10 | 17.3 | 57.7 (27.7–106.1) |
| Unknown causes | 2 |